Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations

Core Insights - Alnylam Pharmaceuticals has experienced a significant decline in share price, dropping nearly 40% from its all-time high since October 2025 [1] Company Performance - The decline in Alnylam's stock is attributed to the company's current phase in the biopharma industry, where investor sentiment is heavily influenced by factors beyond clinical trial outcomes [1]